← Back to Search

Behavioral Intervention

FAMS-T1D Support Program for Type 1 Diabetes (FAMS-T1D Trial)

N/A

Waitlist Available

Research Sponsored by University of Utah

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Persons with diabetes aged 18-24

Diagnosed with T1D and has been taking insulin for at least one year

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline and 6, 9, and 12 months post baseline

Awards & highlights

FAMS-T1D Trial Summary

This trial tests how well an intervention helps young adults with type 1 diabetes set & meet goals, improve their blood glucose, and reduce diabetes distress.

Who is the study for?

This trial is for adults over 18 with Type 1 Diabetes who are comfortable texting and fluent in English. They need a support person who can communicate in English or Spanish. Participants should either have an A1c value of 7.5% or higher, or show signs of diabetes distress. Those with severe mental illness, sensory disabilities, or plans to live abroad during the study cannot join.Check my eligibility

What is being tested?

The FAMS-T1D program aims to help young adults manage their Type 1 Diabetes by setting goals and getting social support. The study checks if this digital intervention improves blood glucose control, self-management, reduces stress related to diabetes, and helps without burdening the support persons.See study design

What are the potential side effects?

Since this trial involves a behavioral intervention using digital resources rather than medication, traditional side effects like those seen with drugs are not expected.

FAMS-T1D Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 24 years old and have diabetes.

Select...

I have Type 1 Diabetes and have been on insulin for over a year.

FAMS-T1D Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline and 6, 9, and 12 months post baseline

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline and 6, 9, and 12 months post baseline

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 6, 9, and 12 months post baseline for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in HbA1c (Person with Diabetes)

Change in Self-Management (Person with Diabetes)

Secondary outcome measures

Diabetes Distress (Person with Diabetes)

Other outcome measures

Change in Diabetes Distress (support person)

Change in Disclosure (Person with Diabetes)

Change in Goal planning (Person with Diabetes)

+9 more

FAMS-T1D Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: FAMS-T1DExperimental Treatment2 Interventions

Participants will receive FAMS-T1D components (monthly phone coaching and text message support for goals) for 6 months. Support person will receive text messages that are tailored to the goal set by the person with type 1 diabetes. All persons with diabetes will receive text messages regarding how to access their HbA1c results and receive links providing information to assist them in self-care behaviors related to their diabetes. All support persons will also receive materials about type 1 diabetes and how to provide helpful support to the person with diabetes.

Group II: Digital resources for diabetesPlacebo Group1 Intervention

Persons with type 1 diabetes will receive text messages as to how to access their HbA1c results and digital materials related to self-care behaviors for their diabetes. All support persons will receive digital materials about type 1 diabetes and how to provide helpful support to the person with diabetes.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of California, MercedOTHER

17 Previous Clinical Trials

5,841 Total Patients Enrolled

Vanderbilt University Medical CenterOTHER

856 Previous Clinical Trials

671,912 Total Patients Enrolled

Children's Hospital Los AngelesOTHER

232 Previous Clinical Trials

5,076,488 Total Patients Enrolled

Media Library

FAMS-T1D (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05820477 — N/A

Type 1 Diabetes Research Study Groups: Digital resources for diabetes, FAMS-T1D

Type 1 Diabetes Clinical Trial 2023: FAMS-T1D Highlights & Side Effects. Trial Name: NCT05820477 — N/A

FAMS-T1D (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05820477 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the enrollment limit for this trial restricted to adults over 18 years of age?

"This trial is specifically catered towards people aged 18 to 24, with 165 studies for minors and 183 separate trials targeting seniors."

Answered by AI

Do I meet the criteria to join this research endeavor?

"This clinical trial is looking for 280 individuals, aged 18 to 24, who are suffering from type 1 diabetes. To be eligible, patients must have a mastery of either English or Spanish and feel comfortable sending and receiving text messages."

Answered by AI

Is recruitment still occurring for this research endeavor?

"This medical trial, which was initially presented to the public on April 1st 2023 and updated on April 7th of the same year, is actively searching for participants."

Answered by AI

How many participants are currently included in this research endeavor?

"Affirmative. According to clinicaltrials.gov, the recruitment process for this trial is in effect; it was posted on April 1st 2023 and last updated on April 7th of the same year. The study requires 280 patients from a single site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

FAMS-T1D Self-Regulation and Social Support for T1D

Cynthia Berg 2023. "FAMS-T1D Self-Regulation and Social Support for T1D". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05820477.